Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early experience with Levosimendan in children with ventricular dysfunction.

Poongundran Namachivayam1, David S Crossland, Warwick W Butt

  • 1Intensive Care Unit, The Royal Children's Hospital, Melbourne, Australia.

Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
|August 4, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Six-Month Outcomes in the Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children Study.

JAMA pediatrics·2025
Same author

Elevating diversity, inclusion, and health equity in Pediatric Heart Network Scholars grant funding: unique opportunities and lessons learned.

Cardiology in the young·2024
Same author

Development and validation of an open-source pipeline for automatic population of case report forms from electronic health records: a pediatric multi-center prospective study.

EBioMedicine·2024
Same author

Attitudes and responses of Victorian paediatric intensive care doctors to the detection and reporting of child maltreatment.

Journal of paediatrics and child health·2024
Same author

An unmet need: arrhythmia detection by implantable loop recorder in the systemic right ventricle.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2023
Same author

COVID-19 in congenital heart disease (COaCHeD) study.

Open heart·2023

Levosimendan, a calcium-sensitizing agent, safely treated critically ill infants and children with severe heart failure. It reduced catecholamine use and improved myocardial performance, especially in acute heart failure cases.

Area of Science:

  • Pediatric Cardiology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Severe heart failure in pediatric patients presents significant challenges, often requiring inotropic support.
  • Current treatments may have limitations, necessitating novel therapeutic agents.

Purpose of the Study:

  • To evaluate the preliminary safety and efficacy of Levosimendan, a novel calcium-sensitizing agent, in critically unwell infants and children with severe heart failure.
  • To assess the impact of Levosimendan on hemodynamic parameters, catecholamine requirements, and myocardial function.

Main Methods:

  • Retrospective cohort analysis of 15 pediatric patients (7 days to 18 years) with severe heart failure requiring inotropic support.
  • Administration of Levosimendan as a single dose (bolus and infusion) under continuous hemodynamic monitoring.

Related Experiment Videos

  • Echocardiographic assessment of ventricular function before and after Levosimendan treatment.

    • Main Results:

    • Levosimendan administration did not significantly alter heart rate, systolic pressure, diastolic pressure, mean blood pressure, or central venous pressure.
    • Catecholamine infusions were discontinued in 10 patients and reduced in 3 others.
    • Overall ejection fraction improved from 29.8% to 40.5% (p = .015), with a significant increase in patients with acute heart failure.

    Conclusions:

    • Levosimendan is safe for use in infants and children experiencing severe heart failure.
    • The drug effectively reduced the need for catecholamine infusions in both end-stage and acute heart failure.
    • Levosimendan demonstrated an objective improvement in myocardial performance, particularly in pediatric patients with acute heart failure.